JPS6221395B2 - - Google Patents
Info
- Publication number
- JPS6221395B2 JPS6221395B2 JP56167678A JP16767881A JPS6221395B2 JP S6221395 B2 JPS6221395 B2 JP S6221395B2 JP 56167678 A JP56167678 A JP 56167678A JP 16767881 A JP16767881 A JP 16767881A JP S6221395 B2 JPS6221395 B2 JP S6221395B2
- Authority
- JP
- Japan
- Prior art keywords
- pressure
- weight
- drug
- sensitive adhesive
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 27
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 26
- 229920000642 polymer Polymers 0.000 claims description 21
- 125000005670 ethenylalkyl group Chemical group 0.000 claims description 15
- 239000010410 layer Substances 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 13
- -1 acrylic ester Chemical class 0.000 claims description 10
- 239000002390 adhesive tape Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 6
- JHPBZFOKBAGZBL-UHFFFAOYSA-N (3-hydroxy-2,2,4-trimethylpentyl) 2-methylprop-2-enoate Chemical compound CC(C)C(O)C(C)(C)COC(=O)C(C)=C JHPBZFOKBAGZBL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000470 constituent Substances 0.000 description 12
- 229920001577 copolymer Polymers 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- SZNYYWIUQFZLLT-UHFFFAOYSA-N 2-methyl-1-(2-methylpropoxy)propane Chemical compound CC(C)COCC(C)C SZNYYWIUQFZLLT-UHFFFAOYSA-N 0.000 description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 8
- 125000005395 methacrylic acid group Chemical group 0.000 description 7
- 229960005205 prednisolone Drugs 0.000 description 6
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 6
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 2
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- OZCMOJQQLBXBKI-UHFFFAOYSA-N 1-ethenoxy-2-methylpropane Chemical compound CC(C)COC=C OZCMOJQQLBXBKI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 1
- CFVWNXQPGQOHRJ-UHFFFAOYSA-N 2-methylpropyl prop-2-enoate Chemical compound CC(C)COC(=O)C=C CFVWNXQPGQOHRJ-UHFFFAOYSA-N 0.000 description 1
- ZVYGIPWYVVJFRW-UHFFFAOYSA-N 3-methylbutyl prop-2-enoate Chemical compound CC(C)CCOC(=O)C=C ZVYGIPWYVVJFRW-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 125000005396 acrylic acid ester group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- PBOSTUDLECTMNL-UHFFFAOYSA-N lauryl acrylate Chemical compound CCCCCCCCCCCCOC(=O)C=C PBOSTUDLECTMNL-UHFFFAOYSA-N 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- NZIDBRBFGPQCRY-UHFFFAOYSA-N octyl 2-methylprop-2-enoate Chemical compound CCCCCCCCOC(=O)C(C)=C NZIDBRBFGPQCRY-UHFFFAOYSA-N 0.000 description 1
- ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Adhesive Tapes (AREA)
Description
【発明の詳細な説明】
本発明は皮膚疾患の治療、消炎、鎮痛等に適し
た治療用接着テープもしくはシートに関する。従
来皮膚に軟膏等の外用薬を塗りこの上をフイルム
で覆い効果的な薬剤の吸収をはかる密封包帯療用
（ODT療法）が普及している。しかし、この密封
包帯療法は患部へのフイルムの取付が面倒である
ばかりでなく、嵩張ること、剥れ易いこと、患部
の面積が大きい場合或は患部の形状が複雑な場合
に患部へ密着しにくいこと等の欠点があつた。こ
れらの欠点をなくすため、感圧性接着剤を不透過
性フイルムに塗布した治療用テープが市販されて
いる。しかしこのようなテープに使用する感圧性
接着剤は、使用中に離脱しないこと、又使用後は
容易に皮膚から剥せることが必要であり、通常こ
のような接着性のバランスをとるため感圧性接着
剤を作るに際し適当な架橋剤を用いる必要があ
る。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a therapeutic adhesive tape or sheet suitable for treating skin diseases, anti-inflammatory, analgesic, etc. Conventionally, occlusive bandage therapy (ODT therapy), in which an external medicine such as an ointment is applied to the skin and then covered with a film, is used to effectively absorb the medicine. However, with this occlusive bandage therapy, not only is it troublesome to attach the film to the affected area, but it is also bulky, easily peels off, and difficult to adhere to the affected area when the area of the affected area is large or the shape of the affected area is complex. There were some drawbacks. To overcome these drawbacks, therapeutic tapes are commercially available in which a pressure-sensitive adhesive is applied to an impermeable film. However, the pressure-sensitive adhesive used in such tapes must not come off during use and must be able to be easily peeled off from the skin after use. It is necessary to use a suitable crosslinking agent when making the adhesive.
しかし架橋剤を使用すると、薬剤の皮膚への移
行性が経時的に悪くなり、感圧性接着剤層に含ま
れる薬剤が有効に利用できず治療効果を次第に低
下させるという欠点を有している。 However, the use of a crosslinking agent has the disadvantage that the transferability of the drug to the skin deteriorates over time, making it impossible to effectively utilize the drug contained in the pressure-sensitive adhesive layer, thereby gradually reducing the therapeutic effect.
例えば、従来アクリル酸エステル又は（及び）
メタクリル酸エステルを構成単位として含む感圧
性接着剤においては、官能基を含有するモノマー
を共重合し、イソシアネート化合物、金属化合物
等の架橋剤を使用することにより凝集力と接着性
の調整を行なうことが行なわれている。 For example, conventional acrylic ester or (and)
For pressure-sensitive adhesives containing methacrylic acid ester as a constituent unit, the cohesive force and adhesiveness can be adjusted by copolymerizing monomers containing functional groups and using crosslinking agents such as isocyanate compounds and metal compounds. is being carried out.
しかしながらかゝる感圧性接着剤においては、
薬剤の皮膚への移行性が経時的に悪くなる欠点が
あつた。 However, in such pressure sensitive adhesives,
The drawback was that the drug's ability to transfer to the skin worsened over time.
本発明の目的は上記の欠点を解消し、感圧性接
着剤層中に含まれる薬剤が効果的に皮膚に移行す
ると共に、その移行性が経時的に変化せず常に安
定した治療効果が得られる治療用テープもしくは
シートを提供することにある。 The purpose of the present invention is to eliminate the above-mentioned drawbacks, and to ensure that the drug contained in the pressure-sensitive adhesive layer is effectively transferred to the skin, and that the transferability does not change over time, providing a stable therapeutic effect. Our objective is to provide therapeutic tapes or sheets.
本発明の要旨は、基材の片面に薬剤を含有する
感圧性接着剤層が設けられてなる治療用接着テー
プもしくはシートにおいて、感圧性接着剤が、(イ)
アクリル酸エステルもしくは（及び）メタクリル
酸エステルを構成成分とする重合体50〜95重量％
と、(ロ)ビニルアルキルエーテルを構成成分とする
重合体50〜５重量％を含有するものである、治療
用接着テープもしくはシートに存する。 The gist of the present invention is to provide a therapeutic adhesive tape or sheet in which a pressure-sensitive adhesive layer containing a drug is provided on one side of a base material, in which the pressure-sensitive adhesive is (a)
50-95% by weight of polymer containing acrylic ester or (and) methacrylic ester as a constituent component
and (b) a therapeutic adhesive tape or sheet containing 50 to 5% by weight of a polymer having vinyl alkyl ether as a constituent component.
次に本発明治療用接着テープもしくはシートに
ついて更に詳細に説明する。 Next, the therapeutic adhesive tape or sheet of the present invention will be explained in more detail.
本発明に用いられる基材としては、ポリエチレ
ン、ポリプロピレン、エチレン―酢酸ビニル共重
合体、軟質ポリ塩化ビニル、セロハン等の可撓性
を有するフイルムもしくはこれらの表面をコロナ
放電等で処理したもの等が好適に使用される。基
材の厚みとしては50〜100ミクロンの範囲が好ま
しい。 The base material used in the present invention includes flexible films such as polyethylene, polypropylene, ethylene-vinyl acetate copolymer, soft polyvinyl chloride, and cellophane, or those whose surfaces have been treated with corona discharge, etc. Preferably used. The thickness of the base material is preferably in the range of 50 to 100 microns.
前記基材上に感圧性接着剤層が設けられる。感
圧性接着剤層は、(イ)アクリル酸エステルもしくは
（及び）メタクリル酸エステルを構成成分とする
重合体50〜95重量％と(ロ)ビニルアルキルエーテル
を構成成分とする重合体50〜５重量％を含有す
る。 A pressure sensitive adhesive layer is provided on the substrate. The pressure-sensitive adhesive layer is made of (a) 50 to 95% by weight of a polymer containing acrylic ester or (and) methacrylic ester as a constituent, and (b) 50 to 5% by weight of a polymer containing vinyl alkyl ether as a constituent. Contains %.
アクリル酸エステルもしくは（及び）メタクリ
ル酸エステルを構成成分とする重合体とは、アク
リル酸エステルの単独重合体、アクリル酸エステ
ル間での共重合体、メタクリル酸エステルの単独
重合体、メタクリル酸エステル間での共重合体、
アクリル酸エステルとメタクリル酸エステルの共
重合体、アクリル酸エステルとこれと共重合しう
る他の単量体との共重合体、メタクリル酸エステ
ルとこれと共重合しうる他の単量体との共重合体
等を意味する。 Polymers containing acrylic esters or (and) methacrylic esters as constituent components include homopolymers of acrylic esters, copolymers of acrylic esters, homopolymers of methacrylic esters, and polymers of methacrylic esters. copolymer,
Copolymers of acrylic esters and methacrylic esters, copolymers of acrylic esters and other monomers that can be copolymerized with them, and copolymers of methacrylic esters and other monomers that can be copolymerized with them. It means a copolymer, etc.
前記アクリル酸エステルとしては、例えばエチ
ルアクリレート、ｎ―ブチルアクリレート、イソ
ブチルアクリレート、イソアミルアクリレート、
２―エチルヘキシルアクリレート、ｎ―オクチル
アクリレート、ラウリルアクリレート等が使用さ
れ、メタクリル酸エステルとしては、メチルメタ
クリレート、ブチルメタクリレート、２―エチル
ヘキシルメタクリレート、ｎ―オクチルメタクリ
レート、ラウリルメタクリレート等が使用され
る。 Examples of the acrylic ester include ethyl acrylate, n-butyl acrylate, isobutyl acrylate, isoamyl acrylate,
2-ethylhexyl acrylate, n-octyl acrylate, lauryl acrylate, etc. are used, and as the methacrylic acid ester, methyl methacrylate, butyl methacrylate, 2-ethylhexyl methacrylate, n-octyl methacrylate, lauryl methacrylate, etc. are used.
ビニルアルキルエーテルを構成成分とする重合
体とは、ビニルアルキルエーテルの単独重合体、
ビニルアルキルエーテル間での共重合体、ビニル
アルキルエーテルとこれと共重合しうる他の単量
体との共重合体等を意味する。 A polymer containing vinyl alkyl ether as a constituent component is a homopolymer of vinyl alkyl ether,
It means a copolymer between vinyl alkyl ethers, a copolymer between a vinyl alkyl ether and another monomer that can be copolymerized with the vinyl alkyl ether, and the like.
前記ビニルアルキルエーテルとしては、例えば
ビニルメチルエーテル、ビニルエチルエーテル、
ビニルイソブチルエーテル等が使用される。 Examples of the vinyl alkyl ether include vinyl methyl ether, vinyl ethyl ether,
Vinyl isobutyl ether and the like are used.
又、上記の他の単量体としては、例えばアクリ
ル酸、メタクリル酸、イタコン酸、アクリルアミ
ド、酢酸ビニル、アクリロニトリル、スチレン等
が使用される。 Examples of the other monomers used include acrylic acid, methacrylic acid, itaconic acid, acrylamide, vinyl acetate, acrylonitrile, and styrene.
前記アクリル酸エステルもしくは（及び）メタ
クリル酸エステルを構成成分とする重合体は、感
圧性接着剤としての性能がすぐれているが、薬剤
との相溶性が充分でなく、薬剤が基材と感圧性接
着剤層との界面に移行して薬剤が有効に利用され
ないものとなつたり、薬剤が感圧性接着剤層と離
型紙との界面に滲出し離型紙に乗移つて有効に移
用されなくなつたり感圧性接着剤層の皮膚への接
着性に悪影響を及ぼす。 Polymers containing acrylic esters and/or methacrylic esters have excellent performance as pressure-sensitive adhesives, but they do not have sufficient compatibility with drugs, and the drugs do not interact with the base material in pressure-sensitive adhesives. The drug may migrate to the interface with the adhesive layer and not be used effectively, or the drug may ooze out to the interface between the pressure-sensitive adhesive layer and the release paper and transfer to the release paper, making it no longer effectively transferred. or adversely affect the adhesion of the pressure-sensitive adhesive layer to the skin.
薬剤が皮膚表面に効率よく移行するものとする
ためには、薬剤が感圧性接着剤層中で容易に拡散
されることが要求され、このため薬剤と感圧性接
着剤とが相溶性を有することが必要となつてく
る。従つて本発明においては薬剤と感圧性接着剤
との相溶性を改善するために、薬剤との相溶性が
すぐれているビニルアルキルエーテルを構成成分
とする重合体を前記のアクリル酸エステルもしく
は（及び）メタクリル酸エステルの重合体と併用
するものである。しかしながらビニルアルキルエ
ーテルを構成成分とする重合体は、薬剤との相溶
性が良好であるがために、薬剤の有する官能基と
相互作用を生じて薬剤の皮膚への移行性を悪くし
やすい。そこでアクリル酸エステルもしくは（及
び）メタクリル酸エステルを構成成分とする重合
体とビニルアルキルエーテルを構成成分とする重
合体の使用割合は、前者が50〜95重量％に対し後
者が50〜５重量％とされる。このように前記の両
重合体の使用量を調整することによつて薬剤の皮
膚への移行性が改善され、薬剤を感圧性接着剤層
から皮膚表面に効率よく移行させることができる
ものとなる。 In order for the drug to transfer efficiently to the skin surface, the drug must be easily diffused in the pressure-sensitive adhesive layer, and therefore the drug and the pressure-sensitive adhesive must be compatible. becomes necessary. Therefore, in the present invention, in order to improve the compatibility between the drug and the pressure-sensitive adhesive, a polymer containing vinyl alkyl ether, which has excellent compatibility with the drug, as a constituent component is added to the above-mentioned acrylic ester or (and ) It is used in combination with a methacrylic acid ester polymer. However, since polymers containing vinyl alkyl ethers have good compatibility with drugs, they tend to interact with the functional groups of drugs and impair the transfer of the drug to the skin. Therefore, the proportion of the polymer containing acrylic ester or (and) methacrylic ester as a constituent and the polymer containing vinyl alkyl ether as a constituent is 50 to 95% by weight for the former and 50 to 5% by weight for the latter. It is said that By adjusting the amounts of both of the above-mentioned polymers used in this manner, the transferability of the drug to the skin is improved, and the drug can be efficiently transferred from the pressure-sensitive adhesive layer to the skin surface. .
アクリル酸エステルもしくは（及び）メタクリ
ル酸エステルを構成成分とする重合体が95重量％
より多量であり、ビニルアルキルエーテルを構成
成分とする重合体が５重量％よりも少量の場合に
は、薬剤が基材と感圧性接着剤層の界面に移行し
たり、離型紙と感圧性接着剤層との界面に移行し
て離型紙に乗移つてしまい易く、皮膚表面への効
率よい移行性は得難くなる。又アクリル酸エステ
ルもしくは（及び）メタクリル酸エステルを構成
成分とする重合体が50重量％よりも少量であり、
ビニルアルキルエーテル構成成分とする重合体が
50重量％よりも多量の場合には、薬剤の有する官
能基とビニルアルキルエーテルを構成成分とする
重合体の相互作用の影響が強くなり、薬剤の皮膚
への移行性が充分なものとならない。 95% by weight of polymers consisting of acrylic esters and/or methacrylic esters
If the amount of the polymer containing vinyl alkyl ether is less than 5% by weight, the drug may migrate to the interface between the base material and the pressure-sensitive adhesive layer, or the release paper and pressure-sensitive adhesive may It tends to migrate to the interface with the agent layer and transfer to the release paper, making it difficult to achieve efficient migration to the skin surface. Further, the amount of the polymer containing acrylic acid ester or (and) methacrylic acid ester as a constituent component is less than 50% by weight,
The polymer as the vinyl alkyl ether component is
If the amount is more than 50% by weight, the effect of the interaction between the functional group of the drug and the polymer containing vinyl alkyl ether as a constituent will be strong, and the drug will not transfer sufficiently to the skin.
本発明における薬剤としては、ヒドロコルチゾ
ン、酢酸ヒドロコルチゾン、プレドニゾロン、デ
キサメタゾン、ベタメタゾン、フルオシノアセト
ニド等の副腎皮質ホルモン；サリチル酸メチル、
サリチル酸モノグリコール等の消炎鎮痛剤；抗ヒ
スタミン剤；抗真菌剤等が目的に応じて適宜使用
される。 The drugs used in the present invention include adrenocortical hormones such as hydrocortisone, hydrocortisone acetate, prednisolone, dexamethasone, betamethasone, and fluocinoacetonide; methyl salicylate;
Anti-inflammatory analgesics such as monoglycol salicylate; antihistamines; antifungals and the like are used as appropriate depending on the purpose.
感圧性接着剤中に含有される薬剤の量として
は、感圧性接着剤層の厚み、薬剤の種類等により
異なるが、感圧性接着剤層１cm2当り１μｇ〜５mg
の範囲が好ましい。 The amount of drug contained in the pressure-sensitive adhesive varies depending on the thickness of the pressure-sensitive adhesive layer, the type of drug, etc., but is 1 μg to 5 mg per 1 cm 2 of the pressure-sensitive adhesive layer.
A range of is preferred.
本発明の治療用接着テープもしくはシートによ
れば、上述の如く構成されているから、使用に際
しての皮膚への貼着性が良好でしかも使用後皮膚
から剥しやすいものとなり、しかも感圧性接着剤
層中に含まれる薬剤が効率よく皮膚に移行すると
ともにその移行性が経時的に変化せず常に安定し
た治療効果を有するものとなる。 According to the therapeutic adhesive tape or sheet of the present invention, since it is constructed as described above, it has good adhesion to the skin during use and is easy to peel off from the skin after use, and has a pressure-sensitive adhesive layer. The drug contained therein is efficiently transferred to the skin, and its transferability does not change over time, resulting in a constant therapeutic effect.
以下、本発明を実施例により説明する。 The present invention will be explained below using examples.
実施例 １
撹拌装置、温度計、冷却管及び窒素導入管の備
えつけられたセパラブルフラスコに２―エチルヘ
キシルアクリレート80重量部、ブチルアクリレー
ト20重量部、酢酸エチル50重量部、重合開始剤と
して過酸化ベンゾイル0.1重量部を仕込み窒素気
流下60℃で48時間重合し共重合体を得た。Example 1 In a separable flask equipped with a stirring device, a thermometer, a cooling tube, and a nitrogen introduction tube, 80 parts by weight of 2-ethylhexyl acrylate, 20 parts by weight of butyl acrylate, 50 parts by weight of ethyl acetate, and benzoyl peroxide as a polymerization initiator were added. 0.1 part by weight was charged and polymerized at 60°C for 48 hours under a nitrogen stream to obtain a copolymer.
又これとは別に、ポリビニルイソブチルエーテ
ルを65重量％溶解した酢酸エチル溶液を調整し
た。 Separately, an ethyl acetate solution containing 65% by weight of polyvinyl isobutyl ether was prepared.
次いで２―エチルヘキシルアクリレート・ブチ
ルアクリレート共重合体80重量部とポリビニルイ
ソブチルエーテル20重量部を含むように、前記２
―エチルヘキシルアクリレート・ブチルアクリレ
ート共重合体とポリビニルイソブチルエーテルの
酢酸エチル溶液を混合し、更に別に調整したプレ
ドニゾロン溶液（重量比でプレドニゾロン：メタ
ノール＝１：49）15重量部を混合した後、厚さ60
μｍのポリエチレンフイルム上に乾燥後の厚みが
50μｍとなるように塗布し、80℃で20分間をかけ
て乾燥した。この場合のプレドニゾロンの含有量
は30μｇ／cm2であつた。 Next, the above-mentioned 2-ethylhexyl acrylate/butyl acrylate copolymer was mixed with 80 parts by weight of 2-ethylhexyl acrylate/butyl acrylate copolymer and 20 parts by weight of polyvinyl isobutyl ether.
- Mix the ethyl acetate solution of ethylhexyl acrylate/butyl acrylate copolymer and polyvinyl isobutyl ether, and then mix with 15 parts by weight of a separately prepared prednisolone solution (prednisolone:methanol = 1:49 by weight), and then form a 60 mm thick
The thickness after drying is
It was coated to a thickness of 50 μm and dried at 80° C. for 20 minutes. The content of prednisolone in this case was 30 μg/cm 2 .
かくして得られた治療用接着テープを水に５時
間浸漬し、抽出されたプレドニゾロン量を測定し
たところ、79重量％であつた。 The therapeutic adhesive tape thus obtained was immersed in water for 5 hours, and the amount of prednisolone extracted was measured and found to be 79% by weight.
比較例 １
実施例１においてポリビニルイソブチルエーテ
ルを存在させないものとする以外は、実施例１と
同様にして治療用接着テープを得た。Comparative Example 1 A therapeutic adhesive tape was obtained in the same manner as in Example 1 except that polyvinyl isobutyl ether was not present.
この治療用接着テープについて実施例１と同様
にして抽出されたプレドニゾロン量を測定したと
ころ、35重量％であつた。 When the amount of prednisolone extracted from this therapeutic adhesive tape was measured in the same manner as in Example 1, it was 35% by weight.
Claims (1)
層が設けられてなる治療用接着テープもしくはシ
ートにおいて、感圧性接着剤が、(イ)アクリル酸エ
ステルもしくは（及び）メタクリル酸エステルを
構成成分とする重合体50〜95重量％と(ロ)ビニルア
ルキルエーテルを構成成分とする重合体50〜５重
量％を含有するものである、治療用接着テープも
しくはシート。1. In a therapeutic adhesive tape or sheet comprising a pressure-sensitive adhesive layer containing a drug on one side of a base material, the pressure-sensitive adhesive comprises (a) an acrylic ester or (and) a methacrylic ester. A therapeutic adhesive tape or sheet containing 50 to 95% by weight of a polymer as a component and 50 to 5% by weight of a polymer comprising (b) vinyl alkyl ether as a component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56167678A JPS5867776A (en) | 1981-10-19 | 1981-10-19 | Adhesive tape or sheet for remedy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56167678A JPS5867776A (en) | 1981-10-19 | 1981-10-19 | Adhesive tape or sheet for remedy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5867776A JPS5867776A (en) | 1983-04-22 |
| JPS6221395B2 true JPS6221395B2 (en) | 1987-05-12 |
Family
ID=15854187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56167678A Granted JPS5867776A (en) | 1981-10-19 | 1981-10-19 | Adhesive tape or sheet for remedy |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5867776A (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS606759A (en) * | 1983-06-24 | 1985-01-14 | Nippon Carbide Ind Co Ltd | Water-dispersible resin for cataplasm |
| JPH0696529B2 (en) * | 1987-03-31 | 1994-11-30 | 積水化学工業株式会社 | Nitroglycerin patch and method for producing the same |
| EP0760339B1 (en) * | 1994-06-02 | 2001-04-04 | Tetra Laval Holdings & Finance Sa | Spout seal opening device for a liquid container |
| JP4153070B2 (en) * | 1998-01-21 | 2008-09-17 | 日東電工株式会社 | Base material for patch, medical patch made using the same, and emergency bandage |
| DE10105278A1 (en) * | 2001-02-02 | 2002-08-08 | Basf Ag | Adhesives containing polyvinyl alkyl ethers |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4915731A (en) * | 1972-03-24 | 1974-02-12 | ||
| JPS5611979A (en) * | 1979-07-12 | 1981-02-05 | Taisho Pharmaceut Co Ltd | Tacky piece |
| JPS56140927A (en) * | 1980-04-07 | 1981-11-04 | Nitto Electric Ind Co Ltd | Medical member |
-
1981
- 1981-10-19 JP JP56167678A patent/JPS5867776A/en active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4915731A (en) * | 1972-03-24 | 1974-02-12 | ||
| JPS5611979A (en) * | 1979-07-12 | 1981-02-05 | Taisho Pharmaceut Co Ltd | Tacky piece |
| JPS56140927A (en) * | 1980-04-07 | 1981-11-04 | Nitto Electric Ind Co Ltd | Medical member |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5867776A (en) | 1983-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW436298B (en) | Transdermal device for the delivery of flurbiprofen | |
| JPH05194201A (en) | Pressure-sensitive silicone adhesive composition for use in percutaneous drug administration apparatus and related medical appliance | |
| JP2007509951A5 (en) | ||
| JP4660830B2 (en) | Transdermal drug delivery system | |
| JPS6221395B2 (en) | ||
| JP3474381B2 (en) | Adhesive composition for skin application | |
| JPH07116023B2 (en) | Patch using polyurethane film as support | |
| JPS6230233B2 (en) | ||
| JPS6221394B2 (en) | ||
| JP3055991B2 (en) | External pharmaceutical preparation | |
| JPS596284B2 (en) | Treatment adhesive tape or sheet | |
| JPH026738B2 (en) | ||
| JPS6320410B2 (en) | ||
| JPH0369884B2 (en) | ||
| JPH0380768B2 (en) | ||
| JPH0335284B2 (en) | ||
| JPS5976019A (en) | Remedial adhesive tape or sheet | |
| JPS5815862A (en) | Medical adhesive tape or sheet | |
| JPH0742228B2 (en) | Pharmaceutical formulation | |
| JPH0229652B2 (en) | ||
| JP3233705B2 (en) | Patch | |
| JPS6126967B2 (en) | ||
| JPH11123235A (en) | Novel sticking agent | |
| JPH0363530B2 (en) | ||
| JPH06239753A (en) | Percutaneous antithrombotic preparation |